close

Fundraisings and IPOs

1 58 59 60 61 62 63
Number of results: 1241
Date Company Amount Funding type Investors Therapeutic area Type of Information
2011-04-19 Circassia (UK) £60 million (€66.8 million) financing round Imperial Innovations (UK) Invesco Perpetual (UK) Allergic diseases - Inflammatory diseases - Respiratory diseases Fundraising
2011-04-19 Circassia (UK) £60 Million (€67 million - $98 Million) fundraising Imperial Innovations (UK) - other existing shareholders, including Invesco Perpetual Allergic diseases - Inflammatory diseases - Respiratory diseases Fundraising
2011-04-14 ArcticZymes (Norway) MNOK 7.2 (€ 0.9 million) grant Research Council of Norway Technology - Services Grant
2011-04-14 Vironova (Sweden) €1,72 million grant European Eurostars Programme (EU) Infectious diseases Grant
2011-04-13 mondoBIOTECH (Switzerland) CHF 8 million (€ 6.2 million) share capital increase shareholders Rare diseases Capital increase
2011-04-12 AB Science (France) € 7,539,400 bond loan agreement shareholders Cancer - Oncology - Neurodegenerative diseases Establishment of a new subsidiary in the EU
2011-04-12 Adenovir Pharma (Sweden) SEK 10.7 million (€ 1.17 million) rights issue BWG Holding - P.U.L.S. AB (Sweden) - Länsförsäkringar Skåne (Sweden) - Sparbanksstiftelsen Skånes Riskkapitalstiftelse (Sweden) - Augmenta Infectious diseases - Ophtalmological diseases Private placement
2011-04-11 Scil Proteins (Germany) €700K grant Investitionsbank Sachsen Anhalt (Germany) Cancer - Oncology Grant
2011-04-09 Algipharma (Norway) grant Cystic Fibrosis Foundation Therapeutics (USA) Rare diseases - Genetic diseases Grant
2011-04-05 Cellectis (France) €12 million capital increase Caisse des dépôts (France) Technology - Services Capital increase
2011-04-05 MDxHealth (Belgium) € 8.2 Million private placement of new shares Cancer - Oncology Private placement
2011-04-05 PathoQuest (France) €2 million series A financing round Kurma Biofund (France) Infectious diseases Fundraising
2011-04-01 Thrombogenics (Belgium) € 173 340 capital increase arising from employee warrant exercises employees Ophtalmological diseases Capital increase
2011-04-01 Neovacs (France) € 2.25 million private placement Debioinnovation (Switzerland) - OTC Asset Management (France) - Truffle Capital (France) Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Private placement
2011-03-31 Acacia Pharma (UK) $10 million (€7 million) Series A financing round Lundbeckfond Ventures (Denmark) - Gilde Healthcare (The Netherlands) Cancer - Oncology Fundraising
2011-03-31 BioVersys (Switzerland) CHF 2.5 millions (€1.9 million) seed financing round EVA (Switzerland) - BioValley Business Angels Club BioBAC (Switzerland) Infectious diseases Fundraising
2011-03-31 to-BBB (The Netherlands) €1.2 million government loan Agentschap NL  (The Netherlands) Cancer - Oncology Subvention
2011-03-30 Galapagos (Belgium) €469,263.67 capital increase arising from employee warrant exercises employees Capital increase
2011-03-28 Anergis (Switzerland) CHF 18 million (€ 13,8 million) Series A financing round Vinci Capital-Renaissance PME (Switzerland)
BioMedInvest (Switzerland)
Sunstone Capital ( Denmark)
Esperante  (Sweden)
Initiative Capital Romandie (Switzerland)
private investors
Allergic diseases - Immunological diseases Series A financing round
2011-03-22 Zealand Pharma (Denmark) Pepscan Therapeutics (The Netherlands) €0.86 million grant European Eurostars Programme (EU) Inflammatory diseases Grant